ArriVent BioPharma Shares Plunge Over 48% After Lung Cancer Trial Fails
ArriVent BioPharma (AVBP) shares plummeted over 48% to an all-time low on Tuesday after the company announced its experimental lung-cancer treatment failed to meet the primary endpoint of a Phase 3 trial. This marks the stock's largest single-day decline.
ArriVent BioPharma shares fell over 48% to a record low on Tuesday after the company said its experimental lung-cancer treatment failed to meet the main goal of a Phase 3 trial. AVBP stock also posted its biggest single-day decline to date. Firmonertinib Misses Main Goal: Phase 3 F…